BACKGROUND: The majority of anal cancers are caused by persistent infections with carcinogenic human papillomaviruses (HPV). Similar to cervical carcinogenesis, the progression from HPV infection to anal cancer occurs through precancerous lesions that can be treated to prevent invasion. In analogy to cervical cytology, anal cytology has been proposed as a screening tool for anal cancer precursors in high-risk populations. METHODS: The authors analyzed the interobserver reproducibility of anal cytology in a population of 363 human immunodeficiency virus (HIV)-infected men who have sex with men (MSM). Liquid-based cytology (LBC) specimens were collected in the anal dysplasia clinic before the performance of high-resolution anoscopy on all patients. Papanicolaou-stained LBC slides were evaluated by 2 cytopathologists, each of whom was blinded to the clinical outcome and the other pathologist's results, using the revised Bethesda terminology. RESULTS: Overall agreement between the 2 observers was 66% (kappa, 0.54; linear-weighted kappa, 0.69). Using dichotomizing cytology results (atypical squamous cells of undetermined significance [ASC-US] or worse vs less than ASC-US), the agreement increased to 86% (kappa, 0.69). An increasing likelihood of testing positive for markers associated with HPV-related transformation, p16/Ki-67, and HPV oncogene messenger RNA was observed, with increasing severity of cytology results noted both for individual cytologists and for consensus cytology interpretation (P value for trend [p(trend)] < .0001 for all). CONCLUSIONS: Moderate to good agreement was observed between 2 cytopathologists evaluating anal cytology samples collected from HIV-positive MSM. A higher severity of anal cytology was associated with biomarkers of anal precancerous lesions. Anal cytology may be used for anal cancer screening in high-risk populations, and biomarkers of HPV-related transformation can serve as quality control for anal cytology.
BACKGROUND: The majority of anal cancers are caused by persistent infections with carcinogenic human papillomaviruses (HPV). Similar to cervical carcinogenesis, the progression from HPV infection to anal cancer occurs through precancerous lesions that can be treated to prevent invasion. In analogy to cervical cytology, anal cytology has been proposed as a screening tool for anal cancer precursors in high-risk populations. METHODS: The authors analyzed the interobserver reproducibility of anal cytology in a population of 363 human immunodeficiency virus (HIV)-infectedmen who have sex with men (MSM). Liquid-based cytology (LBC) specimens were collected in the anal dysplasia clinic before the performance of high-resolution anoscopy on all patients. Papanicolaou-stained LBC slides were evaluated by 2 cytopathologists, each of whom was blinded to the clinical outcome and the other pathologist's results, using the revised Bethesda terminology. RESULTS: Overall agreement between the 2 observers was 66% (kappa, 0.54; linear-weighted kappa, 0.69). Using dichotomizing cytology results (atypical squamous cells of undetermined significance [ASC-US] or worse vs less than ASC-US), the agreement increased to 86% (kappa, 0.69). An increasing likelihood of testing positive for markers associated with HPV-related transformation, p16/Ki-67, and HPV oncogene messenger RNA was observed, with increasing severity of cytology results noted both for individual cytologists and for consensus cytology interpretation (P value for trend [p(trend)] < .0001 for all). CONCLUSIONS: Moderate to good agreement was observed between 2 cytopathologists evaluating anal cytology samples collected from HIV-positive MSM. A higher severity of anal cytology was associated with biomarkers of anal precancerous lesions. Anal cytology may be used for anal cancer screening in high-risk populations, and biomarkers of HPV-related transformation can serve as quality control for anal cytology.
Authors: J R Daling; N S Weiss; T G Hislop; C Maden; R J Coates; K J Sherman; R L Ashley; M Beagrie; J A Ryan; L Corey Journal: N Engl J Med Date: 1987-10-15 Impact factor: 91.245
Authors: William Christopher Mathews; Amy Sitapati; Joseph C Caperna; R Edward Barber; Alyssa Tugend; Unyeong Go Journal: J Acquir Immune Defic Syndr Date: 2004-12-15 Impact factor: 3.731
Authors: Alice Lytwyn; Irving E Salit; Janet Raboud; William Chapman; Teresa Darragh; Barbara Winkler; Jill Tinmouth; James B Mahony; Marie Sano Journal: Cancer Date: 2005-04-01 Impact factor: 6.860
Authors: Michael J Silverberg; Bryan Lau; Amy C Justice; Eric Engels; M John Gill; James J Goedert; Gregory D Kirk; Gypsyamber D'Souza; Ronald J Bosch; John T Brooks; Sonia Napravnik; Nancy A Hessol; Lisa P Jacobson; Mari M Kitahata; Marina B Klein; Richard D Moore; Benigno Rodriguez; Sean B Rourke; Michael S Saag; Timothy R Sterling; Kelly A Gebo; Natasha Press; Jeffrey N Martin; Robert Dubrow Journal: Clin Infect Dis Date: 2012-01-30 Impact factor: 9.079
Authors: Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young Journal: JAMA Date: 2002-04-24 Impact factor: 56.272
Authors: Megan A Clarke; Li C Cheung; Thomas Lorey; Brad Hare; Rebecca Landy; Diane Tokugawa; Julia C Gage; Teresa M Darragh; Philip E Castle; Nicolas Wentzensen Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Anna-Barbara Moscicki; Teresa M Darragh; J Michael Berry-Lawhorn; Jennifer M Roberts; Michelle J Khan; Lori A Boardman; Elizabeth Chiao; Mark H Einstein; Stephen E Goldstone; Naomi Jay; Wendy M Likes; Elizabeth A Stier; Mark L Welton; Dorothy J Wiley; Joel M Palefsky Journal: J Low Genit Tract Dis Date: 2015-07 Impact factor: 1.925
Authors: Lauren M Schwartz; Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Barbara Fetterman; Diane Tokugawa; Thomas S Lorey; Vikrant V Sahasrabuddhe; Patricia Luhn; Julia C Gage; Teresa M Darragh; Nicolas Wentzensen Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Nicolas Wentzensen; Stephen Follansbee; Sylvia Borgonovo; Diane Tokugawa; Lauren Schwartz; Thomas S Lorey; Vikrant V Sahasrabuddhe; Brandon Lamere; Julia C Gage; Barbara Fetterman; Teresa M Darragh; Philip E Castle Journal: AIDS Date: 2012-11-13 Impact factor: 4.177
Authors: Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Diane Tokugawa; Lauren M Schwartz; Thomas S Lorey; Brandon LaMere; Julia C Gage; Barbara Fetterman; Teresa M Darragh; Ana Cecilia Rodriguez; Nicolas Wentzensen Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-11-15 Impact factor: 4.254
Authors: Nicolas Wentzensen; Stephen Follansbee; Sylvia Borgonovo; Diane Tokugawa; Vikrant V Sahasrabuddhe; Jie Chen; Thomas S Lorey; Julia C Gage; Barbara Fetterman; Sean Boyle; Mark Sadorra; Scott Dahai Tang; Teresa M Darragh; Philip E Castle Journal: J Clin Microbiol Date: 2014-06-04 Impact factor: 5.948
Authors: Grant B Ellsworth; Elizabeth A Stier; Elizabeth Y Chiao; Shelly Y Lensing; Teresa Darragh; Naomi Jay; J Michael Berry-Lawhorn; Mark Einstein; Luis F Barroso; Ross D Cranston; Rebecca Levine; Humberto M Guiot; Audrey L French; Stephen E Goldstone; Wolfgang Preiser; Mathilda Claassen; Joel M Palefsky; Timothy J Wilkin Journal: J Acquir Immune Defic Syndr Date: 2021-07-01 Impact factor: 3.771
Authors: Luigi Marongiu; Eric Shain; Lydia Drumright; Reidun Lillestøl; Donald Somasunderam; Martin D Curran Journal: PLoS One Date: 2016-11-09 Impact factor: 3.240